Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE versus HYDELTRASOL.
CELESTONE vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid
Corticosteroid